Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Metabolic Parameters
Treatment-Naïve Patients
Metabolic Parameters vs a TDF-Containing Regimen at 144-Weeks¹
DTG 50mg + 3TC 300mg used in the GEMINI studies.
*The Gemini studies did not determine whether these changes translate to clinical differences
Virologically Suppressed Patients
Metabolic Parameters at 48-Weeks²,³,⁴
The TANGO study did not determine whether these changes translate to clinical differences.
*Defined as homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.2
†Longer-term data required to determine clinical impact of switching to DOVATO from TAF-containing regimens.
‡Defined by the International Diabetes Federation as a combination of risk factors for cardiovascular disease.5
References:
- Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
- van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
- van Wyk J, Ajana F, Bisshop F, et al.Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO study). Presented at: International AIDS Conference; July 21-24, 2019; Mexico City, Mexico. Slides WEAB0403LB.
- van Wyk J, Ait-Khaled M, Santos J, et al. Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): the TANGO study. Presented at: International AIDS Conference; July 6-10, 2020; Virtual. Slides OAB0606.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Published 2006. Updated April 5, 2017. Last Accessed: February 2022. Available at: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: February 2022 PM-IE-DLL-WCNT-200027
